Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
Immune responses against oncolytic adenovirus (Ad) vectors are thought to limit vector anti-tumor efficacy. With Syrian hamsters, which are immunocompetent and whose tumors and normal tissues are permissive for replication of Ad5-based oncolytic Ad vectors, treating with high-dose cyclophosphamide (CP) to suppress the immune system and exert chemotherapeutic effects enhances Ad vector anti-tumor efficacy. However, long-term CP treatment and immunosuppression can lead to anemia and vector spread to normal tissues. Here, we employed three cycles of transient high-dose CP administration plus intratumoral injection of the oncolytic Ad vector VRX-007 followed by withdrawal of CP. Each cycle lasted 4-6 weeks. This protocol allowed the hamsters to remain healthy so the study could be continued for ~100 days. The tumors were very well suppressed throughout the study. With immunocompetent hamsters, the vector retarded tumor growth initially, but after 3-4 weeks the tumors resumed rapid growth and further injections of vector were ineffective. Preimmunization of the hamsters with Ad5 prevented vector spillover from the tumor to the liver yet still allowed for effective long-term anti-tumor efficacy. Our results suggest that a clinical protocol might be developed with cycles of transient chemotherapy plus intratumoral vector injection to achieve significant anti-tumor efficacy while minimizing the side effects of cytostatic treatment.
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, MO, USA.
D
D
Dhar
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, MO, USA.
K
K
Toth
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, MO, USA.
W S M
WS
Wold
D000256:Adenoviridae / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D045744:Cell Line, Tumor; D006224:Cricetinae; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005822:Genetic Vectors / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008647:Mesocricetus; D009374:Neoplasms, Experimental / Q000235:genetics / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000235:genetics / Q000276:immunology / Q000502:physiology*
D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide